Medtronic plc.NYSE: MDT

Medtronic Presents New Nocturia Data for the AltavivaTM Device, Announces National Principal Investigator for the ENDURANCE Study

· Issued by Medtronic plc.

Summary by 6ix AI

At the 47th AUGS Annual Scientific Meeting (AUGS 2026), a medical conference, Medtronic presented updates for Altaviva, its implantable tibial neuromodulation device (an implant that stimulates a nerve in the lower leg). Medtronic says 24-month exploratory findings from its TITAN 2 clinical study show sustained reductions in nightly nocturia episodes (waking at night to urinate).

Key details

  • Medtronic named a national principal investigator, the lead study doctor, for the ENDURANCE study.
  • Medtronic also announced a partnership to advance patient awareness of pelvic floor disorders.

6ix AI wrote this summary from the release below and checked it against the release.

On 6ix: 6ix.com/news/medtronic-presents-new-nocturia-data-for-the-altavivatm-device-announces-national-principal-investigator-for-the-endurance-study

Watch Medtronic's latest callMedtronic PLC. (NYSE:MDT) Q1 2027 Earnings Call · Replay · Sep 1Read the transcript of Medtronic PLC. (NYSE:MDT) Q1 2027 Earnings Call
At 47th AUGS Annual Scientific Meeting, Medtronic advances AltavivaTM clinical program with 24-month exploratory findings from TITAN 2 showing sustained reductions in nightly nocturia episodes and announces partnership to advance patient awareness of pelvic floor disorders Medtronic the global leader in healthcare technology today announced new updates, including clinical evidence, for the Altaviva™ implantable tibial neuromodulation device at AUGS 2026, reinforcing [...]

This is an abstract of the document. To keep reading, click here and get access to the original version.

Medtronic plc. on 6ix

Story so far

Earlier from Medtronic

Later from Medtronic

All Medtronic news releases